Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

Contact Us

Search

Priority Review

Onco_background

Oncology Today—June 2, 2026

This week’s Oncology update highlights precision-oncology momentum across…

Hematology

Hematology Today—January 5, 2026

This hematology roundup brings together major regulatory decisions, global…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital Trends
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Healthcare and Pharma Trends
Rare Disease News
Health Mobile Apps Reports
Neuroscience News
LucidWargames
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Obesity Today—June 2, 2026
Servier Edgewise Sevasemten Deal | Lucid Diligence Brief
Endocrinology Today—June 2, 2026
Haisco Lilly Collaboration | Lucid Diligence Brief
Hematology Today—June 2, 2026

Tags

aesthetic medicine AI in Aesthetics Amycretin atherosclerosis Balstilimab Benign Breast Disease Bezuclastinib blood biomarkers cancer care cancer vaccines Classical Hodgkin lymphoma competitive advantage Dayra Therapeutics Epia Neuro european atherosclerosis society Explainable AI Fenfluramine global development HeartFlow heart valve treatment Hims and Hers Hormone disorder treatments inflammatory skin diseases Inhaled Nintedanib Inhaled Pirfenidone Ischemic heart disease manifold bio MEDI&GENE Medicare Part D molecular design muscarinic Myqorzo Neoantigen vaccine Pain predictive ai prurigo Psychiatric disorders psychiatric genetics Retifanlimab Scancell screening Synthetic Healthcare Data Tecvayli urological cancer vilobelimab

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Obesity Today—June 2, 2026
Servier Edgewise Sevasemten Deal | Lucid Diligence Brief
Endocrinology Today—June 2, 2026
Haisco Lilly Collaboration | Lucid Diligence Brief
Hematology Today—June 2, 2026

TAGS

aesthetic medicine AI in Aesthetics Amycretin atherosclerosis Balstilimab Benign Breast Disease Bezuclastinib blood biomarkers cancer care cancer vaccines Classical Hodgkin lymphoma competitive advantage Dayra Therapeutics Epia Neuro european atherosclerosis society Explainable AI Fenfluramine global development HeartFlow heart valve treatment Hims and Hers Hormone disorder treatments inflammatory skin diseases Inhaled Nintedanib Inhaled Pirfenidone Ischemic heart disease manifold bio MEDI&GENE Medicare Part D molecular design muscarinic Myqorzo Neoantigen vaccine Pain predictive ai prurigo Psychiatric disorders psychiatric genetics Retifanlimab Scancell screening Synthetic Healthcare Data Tecvayli urological cancer vilobelimab

Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy